Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

MediciNova, Inc. (MNOV)’s Stock Jumps on FDA Approval of Second Protocol

On Monday, MediciNova, Inc. (NASDAQ:MNOV)‘s stock ranked among the top gained, jumping by 22% morning trading and then retracting to 15%, after the company said that it had received the approval of a second protocol for a clinical trial. The protocol will evaluate MN-001 (tielukast) for a Nonalcoholic steatohepatitis (NASH) indication and assess if the drug is capable of improving cardiovascular risk. However, Medicinova is a nano-cap company, with a market capitalization of only $88 million, therefore its stock is characterized by a high volatility.


MediciNova, Inc. (NASDAQ:MNOV) is engaged in the biopharmaceutical segment and focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The company will commence a Phase 2 trial that will evaluate the efficacy, safety, and tolerability of MN-001, according to a statement. Last week, MediciNova said that it was in late-stage discussions with investigators at Penn State University regarding the Phase 2 study of MN-001 for the treatment of moderate to severe idiopathic pulmonary fibrosis (IPF).

The stock of MediciNova, Inc. (NASDAQ:MNOV) is up by almost 80% for the last year, as the company has been riding the biotech wave alongside its industry peers. The increase of the stock comes amid the company not reporting any revenues for the last several quarters and posting a net loss of around $0.10 every quarter. However, the latest performance of the majority of biotech stocks shows that it is not surprising for a small company with weak financial results to gain ground lately. Moreover, the stock is still down by 67% since it became public in 2006.

However, the result of the stock gaining ground is not due to a bullish sentiment from the smart money. In fact, out of over 700 funds from our database, the only shareholder of MediciNova, Inc. (NASDAQ:MNOV) is Jim Simons‘ Renaissance Technologies. As of the end of March, Renaissance owns 110,800 shares of the company, down by 5% on the quarter, with an aggregate value of $388,000. In addition, the company has not witnessed any significant insider transactions lately.

Why do we think that it is important to follow the hedge fund sentiment surrounding a stock? We pay attention to hedge funds’ moves because our research has shown that hedge funds are extremely talented at picking stocks on the long side of their portfolios. It is true that hedge fund investors have been underperforming the market in recent years. However, this was mainly because hedge funds’ short stock picks lost a ton of money during the bull market that started in March 2009. Hedge fund investors also paid an arm and a leg for the services that they received. We have been tracking the performance of hedge funds’ 15 most popular stock picks in real time since the end of August 2012. These stocks have returned 135% since then and outperformed the S&P 500 Index by around 80 percentage points (see the details here). That’s why we believe it is important to pay attention to hedge fund sentiment; we also don’t like paying huge fees.

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!